The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Enterobacteriaceae Infection Drug Market Research Report 2025
Synopsis
Enterobacteriaceae infections are caused by Enterobacter species, pathogens responsible for causing severe infections including bacteremia, urinary tract infections, lower respiratory tract infections, skin and soft tissue infections, and intra-abdominal infections.
The global Enterobacteriaceae Infection Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Enterobacteriaceae Infection Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Enterobacteriaceae Infection Drug.
Report Scope
The Enterobacteriaceae Infection Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Enterobacteriaceae Infection Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Enterobacteriaceae Infection Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Genentech
Nanotherapeutics
Novartis
Pfizer
Nymox Pharmaceutical
Sequoia Sciences
Phico Therapeutics
Cantab Biopharmaceuticals
Segment by Type
Beta-lactams Drugs
Carbapenems Drugs
Fluoroquinolones Drugs
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Enterobacteriaceae Infection Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Enterobacteriaceae infections are caused by Enterobacter species, pathogens responsible for causing severe infections including bacteremia, urinary tract infections, lower respiratory tract infections, skin and soft tissue infections, and intra-abdominal infections.
The global Enterobacteriaceae Infection Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Enterobacteriaceae Infection Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Enterobacteriaceae Infection Drug.
Report Scope
The Enterobacteriaceae Infection Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Enterobacteriaceae Infection Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Enterobacteriaceae Infection Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Genentech
Nanotherapeutics
Novartis
Pfizer
Nymox Pharmaceutical
Sequoia Sciences
Phico Therapeutics
Cantab Biopharmaceuticals
Segment by Type
Beta-lactams Drugs
Carbapenems Drugs
Fluoroquinolones Drugs
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Enterobacteriaceae Infection Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Enterobacteriaceae Infection Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Beta-lactams Drugs
1.2.3 Carbapenems Drugs
1.2.4 Fluoroquinolones Drugs
1.2.5 Others
1.3 Market by Application
1.3.1 Global Enterobacteriaceae Infection Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Enterobacteriaceae Infection Drug Market Perspective (2019-2030)
2.2 Enterobacteriaceae Infection Drug Growth Trends by Region
2.2.1 Global Enterobacteriaceae Infection Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Enterobacteriaceae Infection Drug Historic Market Size by Region (2019-2024)
2.2.3 Enterobacteriaceae Infection Drug Forecasted Market Size by Region (2025-2030)
2.3 Enterobacteriaceae Infection Drug Market Dynamics
2.3.1 Enterobacteriaceae Infection Drug Industry Trends
2.3.2 Enterobacteriaceae Infection Drug Market Drivers
2.3.3 Enterobacteriaceae Infection Drug Market Challenges
2.3.4 Enterobacteriaceae Infection Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Enterobacteriaceae Infection Drug Players by Revenue
3.1.1 Global Top Enterobacteriaceae Infection Drug Players by Revenue (2019-2024)
3.1.2 Global Enterobacteriaceae Infection Drug Revenue Market Share by Players (2019-2024)
3.2 Global Enterobacteriaceae Infection Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Enterobacteriaceae Infection Drug Revenue
3.4 Global Enterobacteriaceae Infection Drug Market Concentration Ratio
3.4.1 Global Enterobacteriaceae Infection Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Enterobacteriaceae Infection Drug Revenue in 2023
3.5 Enterobacteriaceae Infection Drug Key Players Head office and Area Served
3.6 Key Players Enterobacteriaceae Infection Drug Product Solution and Service
3.7 Date of Enter into Enterobacteriaceae Infection Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Enterobacteriaceae Infection Drug Breakdown Data by Type
4.1 Global Enterobacteriaceae Infection Drug Historic Market Size by Type (2019-2024)
4.2 Global Enterobacteriaceae Infection Drug Forecasted Market Size by Type (2025-2030)
5 Enterobacteriaceae Infection Drug Breakdown Data by Application
5.1 Global Enterobacteriaceae Infection Drug Historic Market Size by Application (2019-2024)
5.2 Global Enterobacteriaceae Infection Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Enterobacteriaceae Infection Drug Market Size (2019-2030)
6.2 North America Enterobacteriaceae Infection Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Enterobacteriaceae Infection Drug Market Size by Country (2019-2024)
6.4 North America Enterobacteriaceae Infection Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Enterobacteriaceae Infection Drug Market Size (2019-2030)
7.2 Europe Enterobacteriaceae Infection Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Enterobacteriaceae Infection Drug Market Size by Country (2019-2024)
7.4 Europe Enterobacteriaceae Infection Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Enterobacteriaceae Infection Drug Market Size (2019-2030)
8.2 Asia-Pacific Enterobacteriaceae Infection Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Enterobacteriaceae Infection Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Enterobacteriaceae Infection Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Enterobacteriaceae Infection Drug Market Size (2019-2030)
9.2 Latin America Enterobacteriaceae Infection Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Enterobacteriaceae Infection Drug Market Size by Country (2019-2024)
9.4 Latin America Enterobacteriaceae Infection Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Enterobacteriaceae Infection Drug Market Size (2019-2030)
10.2 Middle East & Africa Enterobacteriaceae Infection Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Enterobacteriaceae Infection Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Enterobacteriaceae Infection Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Genentech
11.1.1 Genentech Company Detail
11.1.2 Genentech Business Overview
11.1.3 Genentech Enterobacteriaceae Infection Drug Introduction
11.1.4 Genentech Revenue in Enterobacteriaceae Infection Drug Business (2019-2024)
11.1.5 Genentech Recent Development
11.2 Nanotherapeutics
11.2.1 Nanotherapeutics Company Detail
11.2.2 Nanotherapeutics Business Overview
11.2.3 Nanotherapeutics Enterobacteriaceae Infection Drug Introduction
11.2.4 Nanotherapeutics Revenue in Enterobacteriaceae Infection Drug Business (2019-2024)
11.2.5 Nanotherapeutics Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Enterobacteriaceae Infection Drug Introduction
11.3.4 Novartis Revenue in Enterobacteriaceae Infection Drug Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Enterobacteriaceae Infection Drug Introduction
11.4.4 Pfizer Revenue in Enterobacteriaceae Infection Drug Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 Nymox Pharmaceutical
11.5.1 Nymox Pharmaceutical Company Detail
11.5.2 Nymox Pharmaceutical Business Overview
11.5.3 Nymox Pharmaceutical Enterobacteriaceae Infection Drug Introduction
11.5.4 Nymox Pharmaceutical Revenue in Enterobacteriaceae Infection Drug Business (2019-2024)
11.5.5 Nymox Pharmaceutical Recent Development
11.6 Sequoia Sciences
11.6.1 Sequoia Sciences Company Detail
11.6.2 Sequoia Sciences Business Overview
11.6.3 Sequoia Sciences Enterobacteriaceae Infection Drug Introduction
11.6.4 Sequoia Sciences Revenue in Enterobacteriaceae Infection Drug Business (2019-2024)
11.6.5 Sequoia Sciences Recent Development
11.7 Phico Therapeutics
11.7.1 Phico Therapeutics Company Detail
11.7.2 Phico Therapeutics Business Overview
11.7.3 Phico Therapeutics Enterobacteriaceae Infection Drug Introduction
11.7.4 Phico Therapeutics Revenue in Enterobacteriaceae Infection Drug Business (2019-2024)
11.7.5 Phico Therapeutics Recent Development
11.8 Cantab Biopharmaceuticals
11.8.1 Cantab Biopharmaceuticals Company Detail
11.8.2 Cantab Biopharmaceuticals Business Overview
11.8.3 Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Introduction
11.8.4 Cantab Biopharmaceuticals Revenue in Enterobacteriaceae Infection Drug Business (2019-2024)
11.8.5 Cantab Biopharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Enterobacteriaceae Infection Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Beta-lactams Drugs
Table 3. Key Players of Carbapenems Drugs
Table 4. Key Players of Fluoroquinolones Drugs
Table 5. Key Players of Others
Table 6. Global Enterobacteriaceae Infection Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Enterobacteriaceae Infection Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Enterobacteriaceae Infection Drug Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Enterobacteriaceae Infection Drug Market Share by Region (2019-2024)
Table 10. Global Enterobacteriaceae Infection Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Enterobacteriaceae Infection Drug Market Share by Region (2025-2030)
Table 12. Enterobacteriaceae Infection Drug Market Trends
Table 13. Enterobacteriaceae Infection Drug Market Drivers
Table 14. Enterobacteriaceae Infection Drug Market Challenges
Table 15. Enterobacteriaceae Infection Drug Market Restraints
Table 16. Global Enterobacteriaceae Infection Drug Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Enterobacteriaceae Infection Drug Market Share by Players (2019-2024)
Table 18. Global Top Enterobacteriaceae Infection Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Enterobacteriaceae Infection Drug as of 2023)
Table 19. Ranking of Global Top Enterobacteriaceae Infection Drug Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Enterobacteriaceae Infection Drug Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Enterobacteriaceae Infection Drug Product Solution and Service
Table 23. Date of Enter into Enterobacteriaceae Infection Drug Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Enterobacteriaceae Infection Drug Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Enterobacteriaceae Infection Drug Revenue Market Share by Type (2019-2024)
Table 27. Global Enterobacteriaceae Infection Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Enterobacteriaceae Infection Drug Revenue Market Share by Type (2025-2030)
Table 29. Global Enterobacteriaceae Infection Drug Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Enterobacteriaceae Infection Drug Revenue Market Share by Application (2019-2024)
Table 31. Global Enterobacteriaceae Infection Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Enterobacteriaceae Infection Drug Revenue Market Share by Application (2025-2030)
Table 33. North America Enterobacteriaceae Infection Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Enterobacteriaceae Infection Drug Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Enterobacteriaceae Infection Drug Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Enterobacteriaceae Infection Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Enterobacteriaceae Infection Drug Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Enterobacteriaceae Infection Drug Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Enterobacteriaceae Infection Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Enterobacteriaceae Infection Drug Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Enterobacteriaceae Infection Drug Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Enterobacteriaceae Infection Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Enterobacteriaceae Infection Drug Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Enterobacteriaceae Infection Drug Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Enterobacteriaceae Infection Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Enterobacteriaceae Infection Drug Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Enterobacteriaceae Infection Drug Market Size by Country (2025-2030) & (US$ Million)
Table 48. Genentech Company Detail
Table 49. Genentech Business Overview
Table 50. Genentech Enterobacteriaceae Infection Drug Product
Table 51. Genentech Revenue in Enterobacteriaceae Infection Drug Business (2019-2024) & (US$ Million)
Table 52. Genentech Recent Development
Table 53. Nanotherapeutics Company Detail
Table 54. Nanotherapeutics Business Overview
Table 55. Nanotherapeutics Enterobacteriaceae Infection Drug Product
Table 56. Nanotherapeutics Revenue in Enterobacteriaceae Infection Drug Business (2019-2024) & (US$ Million)
Table 57. Nanotherapeutics Recent Development
Table 58. Novartis Company Detail
Table 59. Novartis Business Overview
Table 60. Novartis Enterobacteriaceae Infection Drug Product
Table 61. Novartis Revenue in Enterobacteriaceae Infection Drug Business (2019-2024) & (US$ Million)
Table 62. Novartis Recent Development
Table 63. Pfizer Company Detail
Table 64. Pfizer Business Overview
Table 65. Pfizer Enterobacteriaceae Infection Drug Product
Table 66. Pfizer Revenue in Enterobacteriaceae Infection Drug Business (2019-2024) & (US$ Million)
Table 67. Pfizer Recent Development
Table 68. Nymox Pharmaceutical Company Detail
Table 69. Nymox Pharmaceutical Business Overview
Table 70. Nymox Pharmaceutical Enterobacteriaceae Infection Drug Product
Table 71. Nymox Pharmaceutical Revenue in Enterobacteriaceae Infection Drug Business (2019-2024) & (US$ Million)
Table 72. Nymox Pharmaceutical Recent Development
Table 73. Sequoia Sciences Company Detail
Table 74. Sequoia Sciences Business Overview
Table 75. Sequoia Sciences Enterobacteriaceae Infection Drug Product
Table 76. Sequoia Sciences Revenue in Enterobacteriaceae Infection Drug Business (2019-2024) & (US$ Million)
Table 77. Sequoia Sciences Recent Development
Table 78. Phico Therapeutics Company Detail
Table 79. Phico Therapeutics Business Overview
Table 80. Phico Therapeutics Enterobacteriaceae Infection Drug Product
Table 81. Phico Therapeutics Revenue in Enterobacteriaceae Infection Drug Business (2019-2024) & (US$ Million)
Table 82. Phico Therapeutics Recent Development
Table 83. Cantab Biopharmaceuticals Company Detail
Table 84. Cantab Biopharmaceuticals Business Overview
Table 85. Cantab Biopharmaceuticals Enterobacteriaceae Infection Drug Product
Table 86. Cantab Biopharmaceuticals Revenue in Enterobacteriaceae Infection Drug Business (2019-2024) & (US$ Million)
Table 87. Cantab Biopharmaceuticals Recent Development
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Enterobacteriaceae Infection Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Enterobacteriaceae Infection Drug Market Share by Type: 2023 VS 2030
Figure 3. Beta-lactams Drugs Features
Figure 4. Carbapenems Drugs Features
Figure 5. Fluoroquinolones Drugs Features
Figure 6. Others Features
Figure 7. Global Enterobacteriaceae Infection Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Enterobacteriaceae Infection Drug Market Share by Application: 2023 VS 2030
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Online Pharmacies Case Studies
Figure 12. Enterobacteriaceae Infection Drug Report Years Considered
Figure 13. Global Enterobacteriaceae Infection Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Enterobacteriaceae Infection Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Enterobacteriaceae Infection Drug Market Share by Region: 2023 VS 2030
Figure 16. Global Enterobacteriaceae Infection Drug Market Share by Players in 2023
Figure 17. Global Top Enterobacteriaceae Infection Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Enterobacteriaceae Infection Drug as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Enterobacteriaceae Infection Drug Revenue in 2023
Figure 19. North America Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Enterobacteriaceae Infection Drug Market Share by Country (2019-2030)
Figure 21. United States Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Enterobacteriaceae Infection Drug Market Share by Country (2019-2030)
Figure 25. Germany Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Enterobacteriaceae Infection Drug Market Share by Region (2019-2030)
Figure 33. China Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Enterobacteriaceae Infection Drug Market Share by Country (2019-2030)
Figure 41. Mexico Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Enterobacteriaceae Infection Drug Market Share by Country (2019-2030)
Figure 45. Turkey Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Enterobacteriaceae Infection Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Genentech Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2019-2024)
Figure 48. Nanotherapeutics Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2019-2024)
Figure 49. Novartis Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2019-2024)
Figure 50. Pfizer Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2019-2024)
Figure 51. Nymox Pharmaceutical Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2019-2024)
Figure 52. Sequoia Sciences Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2019-2024)
Figure 53. Phico Therapeutics Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2019-2024)
Figure 54. Cantab Biopharmaceuticals Revenue Growth Rate in Enterobacteriaceae Infection Drug Business (2019-2024)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
